CN116120436A - anti-HBcAg protein monoclonal antibody and cell strain, preparation method and application thereof - Google Patents
anti-HBcAg protein monoclonal antibody and cell strain, preparation method and application thereof Download PDFInfo
- Publication number
- CN116120436A CN116120436A CN202211471983.8A CN202211471983A CN116120436A CN 116120436 A CN116120436 A CN 116120436A CN 202211471983 A CN202211471983 A CN 202211471983A CN 116120436 A CN116120436 A CN 116120436A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- hbcag protein
- hbcag
- cell strain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 39
- 210000004027 cell Anatomy 0.000 claims abstract description 24
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 15
- 239000000427 antigen Substances 0.000 claims abstract description 10
- 102000036639 antigens Human genes 0.000 claims abstract description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 10
- 238000013115 immunohistochemical detection Methods 0.000 claims abstract description 5
- 230000003248 secreting effect Effects 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 238000003119 immunoblot Methods 0.000 claims description 3
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 6
- 230000007910 cell fusion Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 2
- 210000002955 secretory cell Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- 208000002672 hepatitis B Diseases 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101710142246 External core antigen Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 241000218642 Abies Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5762—Hepatitis B core antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a monoclonal antibody capable of recognizing human HBcAg antigen, a secretory cell strain, a preparation method thereof and application thereof in immunodetection. According to the technical scheme, the natural HBcAg protein is selected to immunize a mouse, and the cell fusion, screening and subcloning are carried out to obtain the mouse hybridoma cell strain 4C2 capable of efficiently secreting the anti-HBcAg protein monoclonal antibody and the anti-HBcAg protein monoclonal antibody secreted by the cell strain. The antibody obtained by the scheme has high specificity and sensitivity, can specifically identify cells expressing HBcAg protein, and is suitable for immunological detection, in particular immunohistochemical detection.
Description
Technical Field
The invention relates to the field of biomedical engineering, in particular to an anti-HBcAg protein monoclonal antibody, a cell strain, a preparation method and application thereof.
Background
It is counted that about 3000 thousands of Chronic Hepatitis B (CHB) patients exist in China at present, and about 30 thousands of patients die from hepatitis B related liver cirrhosis, liver cancer and end-stage liver disease every year, so that a heavy economic burden is brought. The long-term follow-up of 101 patients with HBeAg positive CHB is carried out, and the results show that the expression of HBcAg in the liver of the patients with CHB has different expression types and different expression intensities at the antiviral baseline, the serological conversion rate of HBeAg of the patients with serous and nuclear serous expression after nucleoside antiviral treatment is higher, and the serological conversion rate of HBeAg of the patients with III-level HBcAg expression intensity is also higher.
Research shows that HBcAg has strong immunogenicity, is favorable for activating immune cells of an organism, but is mainly expressed in liver cells and seldom secreted into peripheral blood, so that the regulation effect of HBcAg on the immunity is affected. Wherein, the total anti-HBc and IgM anti-HBc in serum of plasma type and nuclear plasma type expression patients and patients with higher expression of HBcAg in liver are obviously increased, so that when liver inflammation is damaged, HBcAg is exposed or released into blood circulation, and immune cells are activated. Thus, the type and level of expression of HBcAg in hepatocytes may be one of the factors affecting immune function and antiviral efficacy in patients.
Past clinical practice has shown that HBcAg is difficult to detect in serum, mainly because it is not exposed due to HBsAg encapsulation, and it is more difficult to directly stimulate immune cells. In the conversion of the intrahepatic HBcAg from cell nucleus to cytoplasm expression, the quantitative conversion of serum total anti-HBc and IgM type anti-HBc has obvious relation, and when HBV infected patients fluctuate, the HBcAg is exposed from the cell nucleus to cytoplasm and even outside the cell membrane after the hepatic cell injury, and the immune reaction of the organism (especially the B cell reaction generates HBV specific antibody) is activated, which explains the immunological mechanism of the quantitative prediction of the HBc to the serological conversion of the HBeAg after the antiviral treatment of CHB patients to a certain extent. In conclusion, the detection of HBcAg in liver cells plays an important role in predicting antiviral efficacy of nucleoside drugs for patients with CHB.
Disclosure of Invention
The inventor provides a monoclonal antibody of anti-HBcAg protein, wherein the amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4; the amino acid sequence of the monoclonal antibody light chain variable region is the amino acid sequence shown in SEQ ID NO. 5.
Further, the DNA sequence of the heavy chain variable region of the monoclonal antibody is the nucleotide sequence shown as SEQ ID NO.2, and the DNA sequence of the light chain variable region of the monoclonal antibody is the nucleotide sequence shown as SEQ ID NO. 3.
Further, the monoclonal antibody specifically recognizes HBcAg protein.
Further, the monoclonal antibody is mouse IgG 2b Kappa subtype monoclonal antibodies.
Further, the monoclonal antibody is produced by a hybridoma cell strain with a preservation number of CGMCC NO 21974.
The inventor also provides a preparation method of the anti-HBcAg protein monoclonal antibody, wherein an antigen for immunizing mice is HBcAg protein, and the amino acid sequence of the antigen is shown as SEQ ID NO. 1.
The inventor also provides a hybridoma cell strain secreting anti-HBcAg protein molecules, wherein the cell strain is a mouse hybridoma cell strain 4C2, and the cell strain is preserved in China general microbiological culture collection center (CGMCC) NO 21974 at 2021, 3 months and 24 days, and is provided at the microbiological research institute of national academy of sciences of China, 1 st China, 3 rd, beijing, the region of towards the sun.
The inventor also provides an HBcAg protein immunodetection reagent, which contains an amino acid sequence of a heavy chain variable region, wherein the amino acid sequence is shown as SEQ ID NO. 4; the anti-HBcAg protein monoclonal antibody with the amino acid sequence of the light chain variable region shown in SEQ ID NO.5 is taken as an active ingredient.
Further, the immunodetection includes immunohistochemistry, immunoblotting and enzyme-linked immunosorbent assay.
The inventor also provides an HBcAg protein histochemical immunoassay reagent which contains an amino acid sequence of a heavy chain variable region shown in SEQ ID NO. 4; the anti-HBcAg protein monoclonal antibody with the amino acid sequence of the light chain variable region shown in SEQ ID NO.5 is taken as an active ingredient.
Compared with the prior art, the invention has the following beneficial technical effects: according to the technical scheme, natural HBcAg protein is selected as antigen peptide to immunize a mouse, and the cell fusion, screening and subcloning are carried out to obtain a mouse hybridoma cell strain 4C2 capable of efficiently secreting anti-HBcAg protein monoclonal antibodies and the anti-HBcAg protein monoclonal antibodies secreted by the cell strain. The antibody obtained by the scheme has high specificity and sensitivity, can specifically identify cells expressing HBcAg protein, and is suitable for immunological detection, in particular immunohistochemical detection.
Drawings
FIG. 1 is a comparative graph of immunohistochemical staining results of paracancerous liver tissue; wherein the left is HBcAg secreted by 4C2, and the right is commercial HBcAg.
Detailed Description
In order to describe the possible application scenarios, technical principles, practical embodiments, and the like of the present application in detail, the following description is made with reference to the specific embodiments and the accompanying drawings. The embodiments described herein are only used to more clearly illustrate the technical solutions of the present application, and are therefore only used as examples and are not intended to limit the scope of protection of the present application.
Reference herein to "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment may be included in at least one embodiment of the present application. The appearances of the phrase "in various places in the specification are not necessarily all referring to the same embodiment, nor are they particularly limited to independence or relevance from other embodiments. In principle, in the present application, as long as there is no technical contradiction or conflict, the technical features mentioned in the embodiments may be combined in any manner to form a corresponding implementable technical solution.
Unless defined otherwise, technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present application pertains; the use of related terms herein is for the description of specific embodiments only and is not intended to limit the present application.
In the description of the present application, the term "and/or" is a representation for describing a logical relationship between objects, which means that there may be three relationships, e.g., a and/or B, representing: there are three cases, a, B, and both a and B. In addition, the character "/" herein generally indicates that the front-to-back associated object is an "or" logical relationship.
In this application, terms such as "first" and "second" are used merely to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual number, order, or sequence of such entities or operations.
Without further limitation, the use of the terms "comprising," "including," "having," or other like terms in this application is intended to cover a non-exclusive inclusion, such that a process, method, or article of manufacture that comprises a list of elements does not include additional elements but may include other elements not expressly listed or inherent to such process, method, or article of manufacture.
As in the understanding of the "examination guideline," the expressions "greater than", "less than", "exceeding", and the like are understood to exclude the present number in this application; the expressions "above", "below", "within" and the like are understood to include this number. Furthermore, in the description of the embodiments of the present application, the meaning of "a plurality of" is two or more (including two), and similarly, the expression "a plurality of" is also to be understood as such, for example, "a plurality of groups", "a plurality of" and the like, unless specifically defined otherwise.
The HBcAg protein used in this example was purchased from the biotechnology company, tokyo, south kyo, and was extracted from viruses, the accession number in Uniprot database was P03146, and the sequence was the amino acid sequence shown in SEQ ID No. 1.
EXAMPLE 1 establishment of hybridoma cell lines
1. Immunization
HBcAg protein (0.01 mg/mL) from Nanjing Jingda Biotechnology Co., ltd was emulsified with Freund's complete adjuvant (Sigma Co., F5881) and immunized with 4-6 week old female ICR mice (from Beijing Venethol Lihua laboratory animal technologies Co., ltd.) at a dose of 20 μg/mouse by abdominal subcutaneous injection at 6 points. Once every 14 days, the antigen was emulsified with Freund's incomplete adjuvant (Sigma, F5506) at a dose of 20 μg/dose. The polyclonal antibody titer of the anti-immunogen in the serum of the mice was detected by indirect ELISA (wavelength 450 nm) 7 days after the 3 rd booster immunization, the mice with the highest titer were immunized by tail vein injection, and the antigens were uniformly mixed with physiological saline at a dose of 20 mug/mouse.
2. Cell fusion
Sterile preparation of immune-up to-standard mouse spleen cell suspension, mixing with mouse myeloma cell sp2/0 (ATCC NumberCRL-8287) at a ratio of 5:1, centrifuging at 1500rpm for 5min. The supernatant was discarded, the tube was placed in a 37℃water bath, 1ml of PEG1500 (Roche Co.) was slowly added over 1 minute, and the cells were agitated. After standing in warm water for 1min, 10ml of serum-free IMDM (Sigma Co.) was added, mixed well, centrifuged at 1000rpm for 5min. After the supernatant was discarded, 10ml of serum (PAA company) was added and the cells were carefully blown up, and 5ml of thymocytes mixed with 10xHAT (Sigma company) were added and mixed. 25ml of semisolid medium containing 2.1% nitrocellulose (Sigma Co.) was added and mixed well, and then poured into 20 cell culture dishes uniformly. Placing the cell culture dish into a wet box, placing 5% CO at 37deg.C 2 Culturing in an incubator.
3. Cloning and ELISA screening positive hybridoma cells
The size and density of the cloned cell mass are moderate 7 days after fusion, round, solid and large clone mass is sucked into a 96-hole culture plate which is prepared with culture medium in advance under a dissecting lens, and is put into 5% CO at 37 DEG C 2 Culturing in an incubator. After 3 days, the cell mass was approximately 2/3 of the basal area, 100. Mu.L of the supernatant was used for immunizationELISA screening was performed for the raw and synthetic polypeptides, respectively. Positive clones were completely changed and 200. Mu.L of complete medium containing feeder cells and 1% HT (Sigma Co.) was added. Two days later, a second ELISA screening was performed and positive clones were transferred to 24-well plates in which medium (containing feeder cells and HT) was prepared in advance. Five days later, 100 μl of the supernatant was subjected to a third ELISA screening, and positive clones were successively transferred into 6-well plates and cell culture flasks for expansion culture and frozen storage. EXAMPLE 2 preparation of monoclonal antibodies by ascites Induction
1. Ascites preparation
Cells in logarithmic growth phase were washed and suspended in serum-free medium and counted approximately 5X 10 5 1ml. Suspended cells were intraperitoneally injected into mice previously sensitized with paraffin oil. Ascites collection was started after 7 days. The ascites removed was centrifuged at 4000rpm at 4℃for 10min. Carefully aspirate the intermediate ascites and collect in centrifuge tubes and store at 4℃or-20 ℃.
2. Purification of monoclonal antibodies
Antibodies were purified from ascites fluid using HiTrap rProtein A FF (GE company) affinity chromatography as described. SDS-PAGE gel was used to identify purity and concentration was determined by the Bradford method. Purified antibodies were stored at-20 ℃.
EXAMPLE 3 characterization of monoclonal antibodies
1. Subclass identification
The coated sheep anti-mouse IgG (Abies sinensis Biotechnology Co., ltd., beijing) was diluted to 0.5. Mu.g/ml with 100mM PBS (pH 7.4), 100. Mu.l/well was added at 4℃overnight. The liquid was emptied and washed 3 times with PBS containing 0.05% Tween (PBS-T), 200. Mu.l of blocking solution (PBS containing 2% BSA and 3% sucrose) was added to each well and incubated for 1h at 37 ℃. The liquid was emptied and washed 3 times with PBS-T. 0.1ml of hybridoma supernatant was added to each well and incubated at 37℃for 1h. The liquid was emptied and washed 3 times with PBS-T. With blocking liquid 1: HRP-labeled goat anti-mouse (κ, λ) antibody or 1:2000 dilution of HRP-labeled goat anti-mouse (IgM, igG1, igG2a, igG2b, igG3, igA) antibodies (Southern Biotech) 0.1ml were added to the appropriate wells, respectively, and incubated at 37℃for 1h. The liquid was emptied and washed 3 times with PBS-T. Mu.l of a mixture containing 0.15% ABTS (Southern Biotech Co.) and 0.03% H was added to each well 2 O 2 Is subjected to a color reaction in a citric acid buffer (pH 4.0)OD values at 405nm were measured within 10-20 min.
The results show that the monoclonal antibody of the invention is IgG 2 b Kappa-type murine monoclonal antibodies.
2. Affinity constant determination
The purchased HBcAg protein was coated at a concentration of 2. Mu.g/ml, 100. Mu.l/well, coated overnight at 4℃and washed 3 times with PBS-T. Mu.l of blocking solution was added to each well and blocked at 37℃for 2h, and PBS-T was washed 3 times. The monoclonal antibodies purified in example 3, from 1:200 beginning 2-fold gradient dilution, leaving 1 well blank for control, incubating for 1h at 37℃and washing 3 times with PBS-T. HRP-labeled goat anti-mouse secondary antibody 1: diluted 20000, incubated at 37℃for 1h in 100. Mu.l/well and washed 3 times with PBS-T. Mu.l of 0.1% TMB (Sigma Co.) and 0.03% H were added to each well 2 O 2 The reaction was stopped by adding 50. Mu.l of 0.5M sulfuric acid solution after 10min of color development in the citric acid-phosphoric acid buffer. The absorbance at a wavelength of 450nm was measured with a microplate reader. Drawing a curve of OD value corresponding to dilution factor of antibody, finding out dilution factor A corresponding to half of maximum binding OD value, and calculating affinity constant of the antibody to 1.92×10 by using the following formula 9 。
Monoclonal antibody reaction specificity and application effect
The recognition specificity of the monoclonal antibody of the present invention was detected by immunoblotting using the HBcAg recombinant protein prepared in example 1, and 12% polyacrylamide gel electrophoresis was performed. Gel protein bands were transferred onto PVDF membranes (Millipore Corp.) in a Bio-Rad electrotransfer system according to conventional methods. The membranes were placed in TBS-T blocking solution containing 5% nonfat milk powder overnight at 4 ℃. Monoclonal antibodies (1:1000 dilution) to the antibodies secreted by the 41B1 hybridoma were added and incubated overnight at 4 ℃. After washing the membrane with TBS-T, 1: sheep anti-mouse secondary antibody (fir gold bridge biotechnology limited in beijing) diluted at 5000 was incubated for 1 hour at room temperature. The membrane was again washed with TBST, ECL hypersensitivity developing solution (Beijing pride Gene technologies Co., ltd.) was added, and chemiluminescent image data was collected using a ChemiDocMP multicolor fluorescence imaging system (Bio-Rad).
Example 5 determination of variable region sequence of antibodies
Taking fresh hybridoma cells, taking supernatant, performing antigen binding characteristic verification, confirming that cell strain used for cloning can indeed secrete required antibody, and centrifuging and collecting 10 after confirming the result 6 The above hybridoma cells. Trizol method is used to extract total RNA of hybridoma cells, 9. Mu.L of total RNA is taken, 2.5. Mu.L of oligo (dT) 12-18primer (10 mM) and 5. Mu.L of dNTPs are added, and the mixture is uniformly mixed, and the mixture is incubated at 70℃for 5 minutes and then placed on ice for 5 minutes, or subjected to denaturation operation in accordance with the reverse transcriptase used. Then, 5. Mu.L of RT buffer (5X), 2.5. Mu.L of DTT (0.1M) and 1. Mu.L of reverse transcriptase were added and reacted at 42℃for 1 hour. The reaction was terminated by incubating at 70℃for 15 minutes, and the obtained cDNA was stored at-20 ℃. The first strand cDNA obtained was subjected to PCR amplification, 25pmol of each primer was added to a 50. Mu.L reaction system, and the sequences of the primers for heavy chain variable region and light chain variable region amplification were designed and synthesized in accordance with the primer sequences of murine monoclonal antibodies in the book of recombinant antibody (scientific Press, 2005) which was mainly compiled by Shen Beifen.
The rest dNTPs and buffer solution are added according to the conventional method, and finally 1 mu L of cDNA template and 1U of hot start Taq DNA polymerase are added. The PCR amplification procedure was set to 94℃for 40 seconds, 52℃for 40 seconds, 72℃for 40 seconds, 20 to 25 cycles were performed, and finally 72℃was extended for 3 minutes, and the product was allowed to stand by at 4℃or directly electrophoresed. And (3) taking 20 mu L of PCR products for electrophoresis analysis, separating on 1.5% agarose gel, wherein the length of a light chain (kappa light chain) is 320-340bp, the length of a heavy chain is 340-370bp, and performing gel cutting recovery when specific products exist in the region, and cloning to a T vector or an expression vector for sequencing.
EXAMPLE 6 immunohistochemical tissue chip staining and identification
Chip preparation process
HE section staining was performed on each sample to determine tumor sites. The tissue chip was fabricated using a full-automatic tissue chip instrument from 3 DHISTECH. Putting the prepared tissue chip wax block into a wax block manufacturing mould, putting the mould into a 68 ℃ oven for 10 minutes to enable the tissue core and the wax of the receptor wax block to be fused into a whole, then slightly taking out the mould from the oven, cooling the paraffin in a semi-fused state for about 30 minutes at room temperature, putting the mould into a-20 ℃ refrigerator for 6 minutes, taking out the tissue chip wax block from the mould, and slicing or putting the mould into a 4 ℃ refrigerator for preservation for later use. After trimming, continuous slicing is carried out, the thickness is set to be 3 mu m, the continuous slicing is floated in 40% alcohol, the continuous slicing is naturally unfolded, then the separated slices are transferred into warm water with the temperature of 50 ℃ for 30 seconds, the slices are pasted on a glass slide which is treated by polylysine, the prepared tissue chips are placed into an oven with the temperature of 68 ℃ for baking the slices for 2 hours, and the tissue chips are taken out, cooled at room temperature and placed into a refrigerator with the temperature of minus 4 ℃ for preservation.
IHC staining and analysis
Conventional xylenes were dewaxed 3 times for 6 minutes each, hydrated in 100%, 95%, 85% gradient ethanol for 3 minutes each, and finally rinsed with tap water. Antigen retrieval was performed and the sections were then placed in a wet box and rinsed 3 x 3 min in PBS. Dropwise adding 3%H 2 O 2 Incubate for 10min, rinse with PBS for 3 x 3 min. The sections were spun dry, incubated for 1 hour at room temperature (25 ℃) with primary antibody diluted in the appropriate ratio (the dilution ratio of the antibody was designed according to the concentration of the antibody for the first time), washed 3X 3 minutes with PBS, incubated for 15-30 minutes with secondary antibody at room temperature, washed 3X 3 minutes with PBS, spun off the PBS, and developed for 3-10 minutes with freshly prepared DAB developing solution. Hematoxylin counterstain for 25 seconds and PBS returns to blue for 30 seconds. Sequentially dehydrating according to an alcohol gradient of 85% (3 minutes) to 95% (3 minutes) to 100% (3 minutes), and finally making xylene transparent for 3 minutes, and sealing the gel.
Immunohistochemical staining results were divided into: positive and negative. Positive expression must be positive at the cell and tissue specific antigenic sites. Under the conditions of clear tissue staining distribution and accurate cell positioning, the staining results are further divided according to the difference of staining intensity, and the specific steps are as follows:
1. the sample is weak positive; marked as "+";
2. the sample is moderately positive; marked as "++";
3. the sample was highly positive; marked as' ++ ".
4. The sample was negative, labeled "-".
Third, data statistics
1. Tumor tissue chip detection results:
the present antibody HBcAg (4C 2) and commercially available antibody HBcAg (rabbit polyclonal antibody) were synchronously detected in liver tissues beside 20 cases of cancer, and the detection results were compared.
The immunohistochemical results of HBcAg were counted. The whole test process adopts double-blind design, and the statistical result is as follows:
the result shows that the anti-HBcAg protein monoclonal antibody secreted by the 4C2 cell strain has accurate dyeing location, clear dyeing, no nonspecific dyeing and clean background. In immunohistochemical detection, the positive rate was comparable to that of commercially available antibodies, but the positive intensity was higher than that of commercially available antibodies. The HBcAg secreted by the 4C2 cell strain has higher sensitivity, and false negative results are effectively avoided.
FIG. 1 is a graph showing the results of immunohistochemical staining of paracancerous liver tissue (left is 4C2 secreted HBcAg, right is commercially available HBcAg).
2. Normal tissue chip detection results:
the normal tissue chip comprises 30 normal tissue samples, wherein the normal tissue samples are mainly selected from fresh and timely fixed surgical specimens; each tissue included 3 different case samples. The 30 normal tissues include: brain, heart, cerebellum, esophagus, adrenal gland, stomach, ovary, small intestine, pancreas, colorectal, parathyroid, liver, pituitary, salivary gland, testis, kidney, thyroid, prostate, breast, uterus, spleen, bladder, tonsils, skeletal muscle, thymus (young children), skin, bone marrow, peripheral nerves, lung, mesothelial cells.
The antibody (4C 2) and the commercial antibody are synchronously detected on a normal tissue chip, and the detection results of yin and yang are consistent, which shows that the specificity of the antibody in normal tissues is equivalent to that of the commercial antibody.
Finally, it should be noted that, although the foregoing embodiments have been described in the text and the accompanying drawings of the present application, the scope of the patent protection of the present application is not limited thereby. All technical schemes generated by replacing or modifying equivalent structures or equivalent flows based on the essential idea of the application and by utilizing the contents recorded in the text and the drawings of the application, and the technical schemes of the embodiments are directly or indirectly implemented in other related technical fields, and the like, are included in the patent protection scope of the application.
Claims (10)
1. A monoclonal antibody of anti-HBcAg protein, which is characterized in that the amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4; the amino acid sequence of the monoclonal antibody light chain variable region is the amino acid sequence shown in SEQ ID NO. 5.
2. The monoclonal antibody according to claim 1, wherein the DNA sequence encoding the heavy chain variable region of the monoclonal antibody is the nucleotide sequence shown in SEQ ID No.2 and the DNA sequence encoding the light chain variable region of the monoclonal antibody is the nucleotide sequence shown in SEQ ID No. 3.
3. The monoclonal antibody of claim 1, wherein the monoclonal antibody specifically recognizes HBcAg protein.
4. The monoclonal antibody of claim 1, wherein the monoclonal antibody is a mouse IgG 2 b Kappa subtype monoclonal antibodies.
5. A monoclonal antibody of anti-HBcAg protein is produced by a hybridoma cell strain with a preservation number of CGMCC NO 21974.
6. A preparation method of a monoclonal antibody for resisting HBcAg protein is characterized in that an antigen for immunizing mice is the HBcAg protein, and the amino acid sequence of the antigen is shown as SEQ ID NO. 1.
7. A hybridoma cell strain secreting anti-HBcAg protein molecules, wherein the cell strain is a mouse hybridoma cell strain 4C2, and the cell strain is preserved in the China general microbiological culture collection center with the preservation number of: CGMCC NO 21974.
8. An immunoassay reagent for HBcAg protein, characterized in that it comprises the monoclonal antibody against HBcAg protein according to claim 1 as an active ingredient.
9. The immunoassay reagent of claim 8, wherein said immunoassay comprises immunohistochemistry, immunoblotting and enzyme-linked immunoassay.
10. An immunohistochemical detection reagent for HBcAg protein, characterized in that the reagents for immunohistochemical detection comprise the monoclonal antibody against HBcAg protein according to claim 1 as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211471983.8A CN116120436B (en) | 2022-11-23 | 2022-11-23 | anti-HBcAg protein monoclonal antibody and cell strain, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211471983.8A CN116120436B (en) | 2022-11-23 | 2022-11-23 | anti-HBcAg protein monoclonal antibody and cell strain, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116120436A true CN116120436A (en) | 2023-05-16 |
CN116120436B CN116120436B (en) | 2023-10-27 |
Family
ID=86294520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211471983.8A Active CN116120436B (en) | 2022-11-23 | 2022-11-23 | anti-HBcAg protein monoclonal antibody and cell strain, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116120436B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116693666A (en) * | 2023-08-02 | 2023-09-05 | 南方医科大学南方医院 | Monoclonal antibody of anti-hepatitis B core antigen and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107012127A (en) * | 2017-04-01 | 2017-08-04 | 四川迈克生物新材料技术有限公司 | Monoclonal antibody, its purposes and the hybridoma for secreting the monoclonal antibody of anti-hepatitis B virus cAg |
WO2021143902A1 (en) * | 2020-01-19 | 2021-07-22 | 厦门万泰凯瑞生物技术有限公司 | Method and antibody for detecting hbcag |
-
2022
- 2022-11-23 CN CN202211471983.8A patent/CN116120436B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107012127A (en) * | 2017-04-01 | 2017-08-04 | 四川迈克生物新材料技术有限公司 | Monoclonal antibody, its purposes and the hybridoma for secreting the monoclonal antibody of anti-hepatitis B virus cAg |
WO2021143902A1 (en) * | 2020-01-19 | 2021-07-22 | 厦门万泰凯瑞生物技术有限公司 | Method and antibody for detecting hbcag |
Non-Patent Citations (2)
Title |
---|
SOGUT, I: "Monoclonal Antibodies Specific for Hepatitis B e Antigen and Hepatitis B Core Antigen", 《HYBRIDOMA》, vol. 30, no. 5, pages 475 - 479 * |
祝骥: "抗乙肝核心抗原单克隆抗体分离纯化的研究", 《中国优秀博硕士学位论文全文数据库 医药卫生科技辑》, no. 2013, pages 1 - 22 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116693666A (en) * | 2023-08-02 | 2023-09-05 | 南方医科大学南方医院 | Monoclonal antibody of anti-hepatitis B core antigen and application thereof |
CN116693666B (en) * | 2023-08-02 | 2023-10-03 | 南方医科大学南方医院 | Monoclonal antibody of anti-hepatitis B core antigen and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN116120436B (en) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111410690B (en) | anti-CK 19 protein monoclonal antibody, cell line, preparation method and application thereof | |
CN112940118B (en) | Monoclonal antibody of anti-CK 8 protein, cell strain, preparation method and application thereof | |
CN111363043B (en) | anti-CD 20 protein monoclonal antibody, cell line, preparation method and application thereof | |
CN113234161B (en) | anti-CD 3 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113265003B (en) | anti-TdT protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN108659125B (en) | Monoclonal antibody of anti-helicobacter pylori protein, cell strain, preparation method and application thereof | |
CN113278070B (en) | anti-CK 17 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113045652B (en) | anti-DOG 1 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113087793B (en) | anti-CK 14 protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN113072642B (en) | anti-OCT 3/4 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN116120436B (en) | anti-HBcAg protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN116120437B (en) | anti-HBsAg protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113583120B (en) | Monoclonal antibody against CK20 protein, cell strain, preparation method and application thereof | |
CN117946276B (en) | Anti-MCM 2 protein monoclonal antibody, preparation method and application thereof | |
CN113087794A (en) | Monoclonal antibody for resisting HNF1 beta protein, cell strain, preparation method and application thereof | |
CN116178537A (en) | anti-Calretinin protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113735971B (en) | anti-CK 18 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113845592B (en) | anti-CK 5/6 protein monoclonal antibody, cell strain thereof, preparation method and application | |
CN113831410B (en) | anti-CD 56 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN115850468B (en) | Monoclonal antibody of anti-TBX 19 protein, cell strain, preparation method and application thereof | |
CN108467433B (en) | Monoclonal antibody of anti-Napsin A protein, cell strain, preparation method and application thereof | |
CN116903735B (en) | anti-TTF-1 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN115806620B (en) | Monoclonal antibody against HE4 protein, cell strain, preparation method and application thereof | |
CN116003607B (en) | anti-BTLA protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN113307875B (en) | Monoclonal antibody for resisting TCR beta F1 protein, cell strain, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |